ATE319088T1 - Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst - Google Patents

Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst

Info

Publication number
ATE319088T1
ATE319088T1 AT00922683T AT00922683T ATE319088T1 AT E319088 T1 ATE319088 T1 AT E319088T1 AT 00922683 T AT00922683 T AT 00922683T AT 00922683 T AT00922683 T AT 00922683T AT E319088 T1 ATE319088 T1 AT E319088T1
Authority
AT
Austria
Prior art keywords
pepsinogen
pgi
vitamin
concentrations
analyte
Prior art date
Application number
AT00922683T
Other languages
German (de)
English (en)
Inventor
Pentti Sipponen
Matti Haerkoenen
Osmo Suovaniemi
Erik Forsblom
Original Assignee
Biohit Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oy filed Critical Biohit Oy
Application granted granted Critical
Publication of ATE319088T1 publication Critical patent/ATE319088T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
AT00922683T 1999-04-30 2000-04-28 Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst ATE319088T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI990991A FI990991L (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi

Publications (1)

Publication Number Publication Date
ATE319088T1 true ATE319088T1 (de) 2006-03-15

Family

ID=8554566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922683T ATE319088T1 (de) 1999-04-30 2000-04-28 Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst

Country Status (12)

Country Link
EP (1) EP1173764B1 (enExample)
JP (1) JP2002543430A (enExample)
CN (1) CN1353816A (enExample)
AT (1) ATE319088T1 (enExample)
AU (1) AU4299700A (enExample)
DE (1) DE60026285T2 (enExample)
DK (1) DK1173764T3 (enExample)
ES (1) ES2258453T3 (enExample)
FI (1) FI990991L (enExample)
PT (1) PT1173764E (enExample)
RU (1) RU2224258C2 (enExample)
WO (1) WO2000067029A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019L (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
FI20065542A0 (fi) * 2006-09-01 2006-09-01 Biohit Oyj Menetelmä ja näytteenottopakkaus vatsan limakalvon tilan arvioimiseksi
RU2413940C2 (ru) * 2009-02-02 2011-03-10 Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия Способ определения витамина b12 в водных растворах

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97304C (fi) * 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi

Also Published As

Publication number Publication date
JP2002543430A (ja) 2002-12-17
RU2224258C2 (ru) 2004-02-20
DE60026285T2 (de) 2006-11-09
FI990991A0 (fi) 1999-04-30
FI990991A7 (fi) 2000-10-31
FI990991L (fi) 2000-10-31
EP1173764B1 (en) 2006-03-01
CN1353816A (zh) 2002-06-12
DK1173764T3 (da) 2006-05-08
PT1173764E (pt) 2006-06-30
ES2258453T3 (es) 2006-09-01
DE60026285D1 (de) 2006-04-27
AU4299700A (en) 2000-11-17
EP1173764A1 (en) 2002-01-23
WO2000067029A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
WO2003056314A3 (de) Analysensystem zur bestimmung einer analytkonzentration unter berücksichtigung von proben- und analytunabhängigen lichtintensitätsänderungen
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
ATE231017T1 (de) Testsatz und verfahren zur qualitätsprüfung von einem iontophoretischen probenahmesystem
ATE540319T1 (de) Verfahren für die bestimmung von fk506
DE69837015D1 (de) Verfahren zur Stabilisierung und Messung von Troponinkomplexen
DE60315373D1 (de) Vorrichtung und Verfahren zur Bestimmung der Konzentration von Analyten
WO2004099432A3 (en) Identification of biomarkers for detecting pancreatic cancer
DE69920937D1 (de) Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
WO2001075450A3 (en) Fluorescent lifetime assays for non-invasive quantification of analytes
CY1107490T1 (el) Μεθοδος για την ταυτοποιηση δειγματος σε θηλαστικα καθως και κιτ για την εκτελεση αυτης της μεθοδου
WO2004011607A3 (en) Reagent and method for determination of a substance using an immunoaggregator
EP1221620A3 (en) Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity
DE60021369D1 (de) Verfahren zur abschätzung eines magengeschwür-risikos
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE333091T1 (de) Verfahren zur messung von blutersatzstoffen
DE60029413D1 (de) Enzymatische messung von mycophenolsäure
DE60310012D1 (de) Verfahren, Assay und Kit zur Quantifizierung von HIV-Proteasehemmer
ATE469241T1 (de) Verfahren zur vorbehandlung von proben zur bestimmung von verzuckerten aminen, sowie verfahren zur bestimmung von verzuckerten aminen
ATE319088T1 (de) Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst
ATE354088T1 (de) Verfahren zur quantifizierung von oxidiertes glutathion
NO903748L (no) Fremgangsmaate ved enzymatisk bestemmelse av analyttkonsentrasjoner.
CA2586654A1 (en) Use of asc as a marker for colorectal cancer
RU2001132334A (ru) Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1173764

Country of ref document: EP

REN Ceased due to non-payment of the annual fee